Multiple sclerosis natalizumab

Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology. 2006 19(4) 341-9. [Pg.36]

Miller, D. H., Khan, O. A., Sheremata, W. A. et al, International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl J. Med. 348 15-23, 2003. [Pg.651]

Kleinschmidt-DeMasters, B.K., andTyler, K.L., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1 a for multiple sclerosis, N. Engl. J. Med., 353, 2005. [Pg.141]

Tysabri Natalizumab Biogen Idee Anti-alpha 4 Multiple sclerosis 2005... [Pg.580]

Natalizumab Crohn s disease, multiple sclerosis (VLA4Pi)... [Pg.62]

Example 11.1 Natalizumab in the treatment of relapsing multiple sclerosis... [Pg.167]

Example 16.1 Natalizumab plus interferon beta-la for relapsing multiple sclerosis the SENTINEL study... [Pg.258]

Figure 16.1 Patient disposition in the SENTINEL trial. (Rudick RA Stuart WH, Calabresi PA, Confavreux C et at. for the SENTINEL Investigators (2006) Natalizumab plus interferon beta-la for relapsing multiple sclerosis New England Journal of Medicine, 354, 911-923. (2006) Massachusetts Medical Sodety.)...

MUler DH, Khan OA, Sheremata WA, Blumhardt LD et al., for the International Natalizumab Multiple Sclerosis Trial Group (2003) A controUed trial of natalizumab for relapsing multiple sclerosis New England Journal of Medicine, 348, 15-23 Moher D, Schulz KF and Altman DG (2001) The CONSORT statement Revised recommendations for improving the quahty of reports of paraUel-group randomized trials Annals of Internal Medicine, 134, 657-694... [Pg.263]

Natalizumab has shown significant efficacy for a subset of patients with moderate to severe Crohn s disease. Unfortunately, in initial clinical trials of patients with Crohn s disease and multiple sclerosis, 3 of 3100 patients treated with natalizumab developed progressive multifocal leukoencephalopathy due to reactivation of a human... [Pg.1329]

Natalizumab (Tysabri), an anti-a4 integrin monoclonal antibody approved for the treatment of multiple sclerosis, was recently withdrawn from the market temporarily due to cases of progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system associated with immunosuppression [32], These cases highlight our incomplete understanding of the immune system and the translation of preclinical results to humans. [Pg.353]

Tysabri natalizumab (2004) Anti-a4 integrin (mAb-IgG4) Multiple sclerosis Cynomolgus monkey (EFD), Guinea pig (F, EFD, PPD)... [Pg.364]

O Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007 7 123-36. [Pg.376]

Miller DH, BQian OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Wilmer-Hulme AJ, Dalton CM, Miszkiel KA, O Coimor PW, Inti Natalizumab MS Trial Group (2003) A controlled trial of natalizumab for relapsing remitting multiples sclerosis. N Engl J Med 348(1) 15—23. [Pg.601]

O Coimor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, Mitzkiel K, Khan O, Rice F, Sheremata W, Inti Natalizumab Trial Group (2005) Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler Oct 11(5) 568-572. [Pg.601]

Volhner TL, Philips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS (2004) An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Multi Scler Oct 10(5) 511-520. [Pg.602]

Natalizumab Tysarbi (Biogenidec/Elan) Multiple sclerosis... [Pg.273]

Inolimomab Prevention ot graft rejection Keliximab Rheumatoid arthritis Muromonab Prevention ot acute renal allograft rejection Natalizumab Acute relapse in multiple sclerosis Crohn s disease... [Pg.2381]

Polman CH, O Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 354 899-910... [Pg.51]

Natalizumab Tysabri Biogen Idec/Elan humanized mAb VLA4 multiple sclerosis 2004 lgG4 6-10% ... [Pg.1152]

Two drugs initially withdrawn were allowed back by the FDA in U.S. markets. Lotronex (Alosetron, Glaxo Smith Kline) for irritable bowel syndrome was approved in early 2000 and withdrawn 9 months later due to serious gastrointestinal problems. It was reapproved with restrictions in 2002. Tysabri (Natalizumab, Biogen Idee, Elan) for multiple sclerosis was approved in late 2004 and withdrawn in 2005 due to rare fatal brain lesions and was allowed back in mid-2006. [Pg.165]

Natalizumab 4 inlegrin Recombinant endogenous proteins Multiple sclerosis Hypersenisitivy, progressive multifocal leukoencephalopathy (PML)... [Pg.455]

Nervous system Progressive multifocal leukoencephalopathy, due to reactivation of JC virus, occurs in some patients with multiple sclerosis who receive natalizumab, and many so affected die as a result. No new cases occurred during the first 2 years of natalizumab marketing, but by the end of November 2009, there were 28 confirmed cases, of which 8 were fatal. The median... [Pg.593]

Nervous system Subclinical reactivation of JC virus is common in patients with multiple sclerosis who are treated with natalizumab [249 ] and there is an increased risk of JC virus-associated progressive multifocal leukoencephalopathy, which can be fatal or result in severe disability. The risk appears to increase with treatment duration, especially beyond 2 years. There is limited experience in patients who have received natalizumab for more than 3 years and the risk in these patients cannot therefore currently be estimated. [Pg.790]

Yaldizli O, Putzki N. Review natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2009 2(2) 115-28. [Pg.809]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...